Per Lundin
Direttore/Membro del Consiglio presso COMBIGENE AB
Profilo
Dr. Per Lundin is a Chief Executive Officer & Director at Evox Therapeutics Ltd.
He is on the Board of Directors at Evox Therapeutics Ltd., JDRF International and CombiGene AB.
Dr. Lundin was previously employed as a Non-Executive Director by IsletOne Therapeutics and a Manager-European Law Firm Market by Thomson Reuters Holdings AB.
He received his graduate degree from Royal Institute of Technology, an MBA from Stockholm Business School and a doctorate degree from Karolinska Institutet.
Posizioni attive di Per Lundin
Società | Posizione | Inizio |
---|---|---|
COMBIGENE AB | Direttore/Membro del Consiglio | 01/01/2020 |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Fondatore | 01/01/2016 |
JDRF International
JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Per Lundin
Società | Posizione | Fine |
---|---|---|
IsletOne Therapeutics | Fondatore | 01/04/2016 |
Thomson Reuters Holdings AB | Corporate Officer/Principal | 01/04/2016 |
Formazione di Per Lundin
Karolinska Institutet | Doctorate Degree |
Royal Institute of Technology | Graduate Degree |
Stockholm Business School | Masters Business Admin |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
COMBIGENE AB | Health Technology |
Aziende private | 4 |
---|---|
JDRF International
JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Commercial Services |
Thomson Reuters Holdings AB | |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Health Technology |
IsletOne Therapeutics |
- Borsa valori
- Insiders
- Per Lundin